Hims & Hers to shut down dermatology business Apostrophe
Apostrophe is being shut down to "simplify its (company's) dermatology products and operations into one seamless experience," Hims & Hers said.
The telehealth company, which also offers products for skin conditions such as wrinkles and fine lines, had acquired Apostrophe in 2021.
Hims & Hers will continue to provide other dermatology treatments.
A notice on Apostrophe's website also said the business is being discontinued and all current subscriptions will be canceled.
Shares of the telehealth firm closed 4.5% higher at $35.95 on Friday. The company's stock has plunged more than 45% since Novo Nordisk's (NOVOb.CO), opens new tab drug semaglutide, the active ingredient in its top-selling medicines Wegovy and Ozempic, was removed from the U.S. health regulator's shortage list on February 21.
Compounding pharmacies and telehealth firms such as Hims & Hers had been allowed to produce hundreds of thousands of doses of copies of weight-loss drugs Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound, only while the FDA said there was a shortage of them.
Without a shortage, compounders may not produce copies of the branded drugs regularly or in large amounts, according to FDA guidance. The regulator has given a grace period of 60 to 90 days to compounding pharmacies, starting the clock on unfettered market access for these drugs.
Hims & Hers has said it cannot guarantee the continuity of the products "in the same manner, to the same extent, or at all".
The company plans to continue the sale of personalized doses of the drug along with its nutrition and coaching plans. It said that the decision to wind down Apostrophe is unrelated and separate from its weight-loss drug business.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
31 minutes ago
- Reuters
US FDA's top vaccine official Vinay Prasad leaves agency after short stint
July 29 (Reuters) - The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director of the Center for Biologics Evaluation and Research, a government spokesperson said late on Tuesday. Prasad, an oncologist who previously criticized the FDA and was a fierce critic of U.S. COVID-19 vaccine and mask mandates, had been appointed in May. "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," a spokesperson from the Department of Health and Human Services told Reuters in an emailed statement. Endpoints News first reported Prasad's departure. His exit comes after a number of unusual regulatory actions, including those taken recently by the agency on Sarepta Therapeutics'(SRPT.O), opens new tab gene therapy, Elevidys. "Unprecedentedly, there were multiple press leaks from the FDA, negatively impacting (its) credibility," said BMO Capital Markets analyst, Koustas Billouri. During Prasad's short stint, the U.S. FDA limited the use of COVID-19 vaccines and declined to approve therapies from Replimmune (REPL.O), opens new tab and Capricor Therapeutics (CAPR.O), opens new tab. The regulator's decisions under Prasad raised concerns that he was anti-patient choice, Jefferies analyst Roger Song said, adding that investors will see his departure as a positive for gene therapy and vaccine makers. The Nasdaq Biotechnology Index (.NBI), opens new tab declined 7% on Prasad's appointment, but has since recovered. Shares of Replimmune rose 58%, Sarepta was up 11.2% and Capricor added 21.2% in premarket trading on Wednesday. Prasad also held the additional role of the agency's chief medical and science officer, to which he was appointed last month, according to STAT News. Nominating a more seasoned official to replace him could help the FDA rebuild its credibility, BMO's Billouri said.
Reuters
2 hours ago
- Reuters
Novo Nordisk shares fall further as new CEO faces US challenges
COPENHAGEN, DENMARK, July 30 (Reuters) - Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value. Novo Nordisk on Tuesday slashed its outlook for 2025 sales growth and said it had appointed veteran insider Maziar Mike Doustdar as its new CEO. Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, was worth as much as $615 billion at its peak in June last year. But its shares have fallen by two-thirds on concerns the drugmaker is losing ground in the obesity drug race. Shares closed down 23% on Tuesday after trading as much as 30% lower. On Wednesday, they had fallen a further 3.1% by 0846 GMT. Novo said the lower sales outlook reflected competition from "compounded" copycats to Wegovy - custom-made medicines that are based on the same ingredients as branded drugs - which took investors by surprise. The company's management failed to reassure investors on a call with investors and analysts on Tuesday, when incoming CEO Doustdar stated that "we are having a fantastic growth right now with Wegovy". "This has really become a severe credibility issue," said Barclays analyst Emily Field. "They don't view the issues that they have as severely as the market does, and that's creating a big problem." Barclays downgraded the stock to "equal-weight" from "overweight". Novo on Tuesday said it was intensifying its efforts to regain patients taking compounded versions, and had stepped up dialogue with the U.S. FDA to limit unlawful compounding. JPMorgan kept its "overweight" recommendation on the stock but cut its target price to 500 crowns from 650 crowns. Its analysts said in a research note that they expect the company to return to growth in U.S. scripts in the near term, but "would not be surprised to see investors remaining cautious pending evidence of execution against the new targets".
Reuters
6 hours ago
- Reuters
European stocks close up; Novo Nordisk logs its biggest daily drop on record
July 29 (Reuters) - European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest one-day drop of the year as Novo Nordisk's shares slid after the weight-loss drug maker issued a profit warning. The Wegovy producer ( opens new tab, once a market darling, logged its biggest one-day drop on record of 23%, wiping about $57.5 billion off its market value, as it slashed its outlook for 2025 sales growth and named a new CEO as it battles rising competition in the obesity drug market. The stock weighed on Denmark's Copenhagen OMX index (.OMXC20), opens new tab, which lost 11.9%, while the broader STOXX pharmaceutical sector (.SXDP), opens new tab slid 1.6%. "It's doubly disappointing for investors when you find a company that had been anticipated to be a real star in a booming sector, and they don't seem to be able to capitalize on what was a really good competitive position," said Danni Hewson, head of financial analysis at AJ Bell. The stock "seems to be getting pummeled" by its U.S. rival, Eli Lilly, Hewson said. "Now we are seeing a change in CEO, but investors are not going to give the new guy an awful lot of time to get the house in order." Eli Lilly (LLY.N), opens new tab also lost 5% in afternoon trading. More broadly the pan-European STOXX 600 index (.STOXX), opens new tab finished 0.3% higher, with banks (.SX7P), opens new tab gaining 1.7% to hit their highest since September 2008 as investors bet on improved profits and resilience in a sector broadly insulated from tariff turmoil. In a relief for investors, the U.S. and EU signed an agreement to lower U.S. tariffs to 15%, ending weeks of negotiations earlier this week and offering investors some clarity on the trade front. Analysts said the corporate earnings landscape has markedly improved following the deal, and they now project European companies to deliver 1.8% growth in second-quarter earnings compared to a 0.3% decline just a week earlier, according to LSEG I/B/E/S data. Aerospace and defence stocks (.SXPARO), opens new tab added 2.2% after three straight days of losses. The new framework trade deal offered zero-for-zero tariffs on aircraft and parts. Airbus and Safran SA gained 1.7% and 2.1%, respectively. Franco-Italian eyewear group EssilorLuxottica ( opens new tab shares jumped 6.9% after the company reported an increase in first-half operating profit despite a tariff hit. Dutch company Philips ( opens new tab rose 9.2% to the top of the index after the healthcare technology group lowered its tariff impact estimates following the U.S.-EU trade deal. Attention now turns to Wednesday's second-quarter GDP releases from both the euro zone and the U.S., followed by the Federal Reserve's highly anticipated rate decision and Friday's U.S. employment report. ($1 = 0.8663 euros)
